NCT07476326 2026-03-17
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
Clinical Trials
11 trialsNCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Phase 1 Active not recruiting
NCT07276373 2026-02-27
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Phase 1/2 Recruiting
NCT03400332 2026-02-24
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03686124 2026-02-18
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT05533697 2026-02-06
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT06880549 2026-02-05
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting